LDLR and atherosclerosis: In high-fat fed LDL receptor KOmice treatment with tesaglitazar for 12 weeks was associated also with adecrease in atherosclerosis in female mice in the absence of alterations incholesterol or triglyceride levels or a reduction in the inflammatory markersserum amyloid A and serum amyloid P [108].The reasons for these conflicting results are unclear.